Literature DB >> 9764991

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages.

R Terg1, K Llano, S M Cobas, C Brotto, A Barrios, D Levi, W Wasen, M A Bartellini.   

Abstract

BACKGROUND/AIMS: Selective intestinal decontamination has been proposed to prevent spontaneous bacterial peritonitis in cirrhosis. Because of the cost of antibiotics and the development of resistant bacteria, we have evaluated the effect of different schemes and doses of oral ciprofloxacin on aerobic gram-negative fecal flora in cirrhotic patients.
METHOD: Twenty-nine cirrhotic patients were allocated to four groups to receive: Group 1: 500 mg/day for 2 weeks (six patients); Group 2: 1000 mg twice a week for 2 weeks (six patients); Group 3: 1000 mg once a week for 2 weeks (six patients); and Group 4: 1000 mg once a week for 12 weeks (11 patients). Quantitative analysis of the gram-negative fecal flora was performed before and 1 and 2 weeks after initiation of treatment in patients in Groups 1, 2 and 3 and before and 4, 8 and 12 weeks after initiation of treatment in patients in Group 4.
RESULTS: Complete eradication of gram-negative bacilli was observed in four of six patients in Group 1. In contrast, only one patient eradicated gram-negative bacilli in Group 2 and Group 3. In long-term administration of ciprofloxacin (Group 4), only two of 11 patients had persistent eradication of gram-negative bacilli. Four patients developed E. coli resistant to ciprofloxacin (one of them associated to resistant Klebsiella). No patient developed bacterial infection during the study period.
CONCLUSION: Oral ciprofloxacin administered in a weekly dose is ineffective in selective intestinal decontamination. Different mechanisms, including the emergence of ciprofloxacin-resistant organisms, could account for this failure. Therefore, our results suggest that weekly administration of ciprofloxacin is not useful in preventing spontaneous bacterial peritonitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764991     DOI: 10.1016/s0168-8278(98)80062-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Ciprofloxacin: Spontaneous Bacterial Peritonitis (Prevention).

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2015-09-16

2.  Spontaneous bacterial peritonitis: few additional points.

Authors:  Pankaj Jain
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

Review 3.  Gut microbiota-related complications in cirrhosis.

Authors:  Isabel Gómez-Hurtado; José Such; Yolanda Sanz; Rubén Francés
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Spontaneous Bacterial Peritonitis.

Authors:  Donald J. Hillebrand
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

Review 5.  Drug treatment of the complications of cirrhosis in the older adult.

Authors:  B S Anand
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Impact of prolonged treatment with high-dose ciprofloxacin on human gut flora: a case report.

Authors:  Irene S Kourbeti; Dimitrios E Alegakis; Sofia Maraki; George Samonis
Journal:  J Med Case Rep       Date:  2010-04-21

7.  Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study.

Authors:  Jeong Heo; Yeon Seok Seo; Hyung Joon Yim; Taeho Hahn; Sang Hoon Park; Sang Hoon Ahn; Jun Yong Park; Ji Young Park; Moon Young Kim; Sung Keun Park; Mong Cho; Soon Ho Um; Kwang Hyub Han; Hong Soo Kim; Soon Koo Baik; Byung Ik Kim; Se Hyun Cho
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

Review 8.  Cirrhosis and its complications: evidence based treatment.

Authors:  Salman Nusrat; Muhammad S Khan; Javid Fazili; Mohammad F Madhoun
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 9.  Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies.

Authors:  Sebastián Marciano; Juan Manuel Díaz; Melisa Dirchwolf; Adrián Gadano
Journal:  Hepat Med       Date:  2019-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.